Nature journal publishes Metabolon's genome wide association study

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced the publication of "Human Metabolic Individuality in Biomedical and Pharmaceutical Research" in the journal Nature. This groundbreaking Genome Wide Association Study (GWAS) establishes the strong association of biochemical levels with the genetics of an individual and illustrates the power of combining metabolomics with genomics analyses. The study was carried out by researchers at Helmholtz Zentrum Munchen Institute in Munich, Germany, the Wellcome Trust/Sanger Centre, King's College and Metabolon, Inc.

Historically, GWAS have identified risk loci for some diseases but studies have been limited in size, the effect size of the associations have typically been relatively small, and an immediate biological linkage or understanding is often missing. The newly published study overcomes many of these limitations.

"This is by far the most comprehensive GWAS to investigate the association of biochemical levels in blood with human genetics," said Dr. John Ryals, President and CEO of Metabolon. "The associations uncovered in this work provide new functional insights for many disease-related associations that have been reported in previous studies, including cardiovascular and kidney disorders, type 2 diabetes, cancer, gout, venous thromboembolism, and Crohn's disease."

Metabolomic profiling was performed on fasting serum collected from 2,820 individuals who were participants in the German KORA F4 study.

"Using Metabolon's technology platform we measured more than 250 metabolites covering over 60 biochemical pathways, analyzing a total of 2820 individual blood samples from two separate cohorts rapidly (24 minutes/sample) and with low median process variability (<12%)," emphasized Dr. Mike Milburn, Metabolon's Chief Scientific Officer.

This study establishes biochemistry, perhaps the most easily measured genetic trait, as an intermediate to provide a biological link that contributes to the understanding of the genetic effects and more effectively impacts discovery and development of individualized biomarkers and therapies.

"The exceptionally large effect sizes of 10-60% per allele copy for 25 specific loci suggests that testing biochemical levels—beyond inborn errors of metabolism—is likely an excellent way of understanding individual uniqueness and can potentially increase the development of personalized medicine," said Dr. Craig Venter, Founder and President of the J. Craig Venter Institute and a Scientific Advisor to Metabolon.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
What impact has SARS-CoV-2 variant B.1.1.519 had on Mexico City?